Search

Your search keyword '"DI Napoli D"' showing total 66 results

Search Constraints

Start Over You searched for: Author "DI Napoli D" Remove constraint Author: "DI Napoli D"
66 results on '"DI Napoli D"'

Search Results

3. Oxidative damage and cytotoxic cell involvement in the neuronal pathogenesis of mucopolysaccharidosis IIIB

4. Lentiviral vector-mediated gene therapy for Sanfilippo B syndrome (MPS IIIB)

5. Gene therapy of Sanfilippo type B syndrome using a lentiviral vector

6. Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB

11. Biliverdin Protects against Liver Ischemia Reperfusion Injury in Swine

17. Human CD34+ stem cells produce bone nodules in vivo.

19. Limited Transgene Immune Response and Long-Term Expression of Humanα-L-Iduronidase in Young Adult Mice with Mucopolysaccharidosis Type I by Liver-Directed Gene Therapy

20. Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study

21. A rat model of acute kidney injury through systemic hypoperfusion evaluated by micro-US, color and PW-Doppler

22. Worsening of Cardiomyopathy Using Deflazacort in an Animal Model Rescued by Gene Therapy

23. Activation of stress kinases in the brain of mucopolysaccharidosis IIIB mice

24. Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB

25. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector

26. Biliverdin Protects against Liver Ischemia Reperfusion Injury in Swine

27. T.O. 6 Systemic delta-sarcoglycan gene transfer into cardiomyopathic BIO14.6 hamsters by AAV

29. The favourable alliance between CardioMEMS and levosimendan in patients with advanced heart failure.

30. Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists.

31. Performances of HEART score to predict 6-month prognostic of emergency department patients with chest pain: a retrospective cohort analysis.

32. Role of cardiological specialistic evaluation in patients with chest pain presenting in the emergency department.

33. Biobanking for COVID-19 research.

34. A Pilot Study of the Efficacy and Economical Sustainability of Acute Coronavirus Disease 2019 Patient Management in an Outpatient Setting.

35. Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine.

36. Stranger Months: How SARS-CoV-2, Fear of Contagion, and Lockdown Measures Impacted Attendance and Clinical Activity During February and March 2020 at an Urban Emergency Department in Milan.

37. Novel Coronavirus Disease (COVID-19) in Italian Patients: Gender Differences in Presentation and Severity.

38. Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study.

39. [The IRCCS San Raffaele Hospital organizational model to assess the clinical documentation completeness and the appropriateness of hospitalization: the SVAD experience and the results of the three-year period 2018-2020.]

40. Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency

41. A rat model of acute kidney injury through systemic hypoperfusion evaluated by micro-US, color and PW-Doppler.

42. Prevalence of Takayasu arteritis in young women with acute ischemic heart disease.

43. Induction of VX2 para-renal carcinoma in rabbits: generation of animal model for loco-regional treatments of solid tumors.

44. The Murine Model of Mucopolysaccharidosis IIIB Develops Cardiopathies over Time Leading to Heart Failure.

45. Biliverdin protects against liver ischemia reperfusion injury in swine.

46. Unfolded protein response is not activated in the mucopolysaccharidoses but protein disulfide isomerase 5 is deregulated.

47. Activation of stress kinases in the brain of mucopolysaccharidosis IIIB mice.

48. Btk regulation in human and mouse B cells via protein kinase C phosphorylation of IBtkγ.

49. Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy.

50. Serum MIP-1 alpha level: a biomarker for the follow-up of lentiviral therapy in mucopolysaccharidosis IIIB mice.

Catalog

Books, media, physical & digital resources